Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Protocol compliance of target volumes and organs at risk in the first and final submission

From: Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case

Target volumes/ Organs at risk

Dose parameters

First submission (n = 26)

Final submission (n = 26)

P value‡

Optimal No. (%)

Acceptable No. (%)

Optimal plus acceptable No. (%)

Optimal No. (%)

Acceptable No. (%)

Optimal plus acceptable No. (%)

PTVcw

V100%

7 (26.9)

11 (42.3)

18 (69.2)

11 (42.3)

14 (53.8)

25 (96.2)

0.016

Dmax/V120%

20 (76.9)

4 (15.4)

24 (92.3)

15 (57.7)

10 (38.5)

25 (96.2)

1.000

V110%

23 (88.5)

2 (7.7)

25 (96.2)

23 (88.5)

3 (11.5)

26 (100.0)

1.000

PTVsc + ax

V100%

15 (57.7)

5 (19.2)

19 (76.9)

13 (50.0)

13 (50.0)

26 (100.0)

0.031

Dmax/V120%

23 (88.5)

3 (11.5)

26 (100.0)

24 (92.3)

2 (7.7)

26 (100.0)

NA

V110%

23 (88.5)

2 (7.7)

25 (96.2)

22 (84.6)

3 (11.5)

25 (96.2)

1.000

PTVim

V100%

9 (34.6)

5 (19.2)

14 (53.8)

8 (30.8)

15 (57.7)

23 (88.5)

0.012

Dmax/V120%

24 (92.3)

2 (7.7)

26 (100.0)

25 (96.2)

1 (3.8)

26 (100.0)

NA

V110%

24 (92.3)

0

24 (92.3)

24 (92.3)

1 (3.8)

25 (96.2)

1.000

Heart

Dmean

4 (15.4)

15 (57.7)

19 (73.1)

2 (7.7)

24 (92.3)

26 (100.0)

0.016

V5Gy

17 (65.4)

3 (11.5)

20 (76.9)

22 (84.6)

3 (11.5)

25 (96.2)

0.125

LADCA

V40Gy

3 (11.5)

7 (26.9)

10 (38.5)

7 (26.9)

10 (38.5)

17 (65.4)

0.039

Ipsilateral lung

Dmean

11 (42.3)

8 (30.8)

19 (73.1)

14 (53.8)

8 (30.8)

22 (84.6)

0.250

V20Gy

12 (46.2)

13 (50.0)

25 (96.2)

17 (65.4)

9 (34.6)

26 (100.0)

1.000

V5Gy

9 (34.6)

8 (30.8)

17 (65.4)

11 (42.3)

13 (50.0)

24 (92.3)

0.016

Contralateral lung

V5Gy

20 (76.9)

4 (15.4)

24 (92.3)

21 (80.8)

4 (15.4)

25 (96.2)

1.000

Contralateral breast

Dmean

20 (76.9)

6 (23.1)

26 (100.0)

23 (88.5)

3 (11.5)

26 (100.0)

NA

Spinal Cord PRV

Dmax

22 (84.6)

3 (11.5)

25 (96.2)

26 (100.0)

0

26 (100.0)

1.000

Esophagus

Dmax

21 (80.8)

5 (19.2)

26 (100.0)

23 (88.5)

3 (11.5)

26 (100.0)

NA

Ipsilateral Brachial plexus

Dmax

13 (50.0)

11 (42.3)

24 (92.3)

9 (34.6)

15 (57.7)

24 (92.3)

1.000

Ipsilateral shoulder joint

V30

12 (46.2)

4 (15.4)

16 (61.5)

16 (61.5)

5 (19.2)

21 (80.8)

0.125

Thyroid gland

Dmean

15 (57.7)

9 (34.6)

24 (92.3)

16 (61.5)

9 (34.6)

25 (96.2)

1.000

Liver

V5

21 (80.8)

2 (7.7)

23 (88.5)

26 (100.0)

0

26 (100.0)

NA

Stomach

V5

10 (38.5)

4 (15.4)

14 (53.8)

18 (69.2)

6 (23.1)

24 (92.3)

0.002

  1. PTVcw, chest wall planning target volume; PTVsc + ax, supraclavicular fossa plus axilla levels I, II, III planning target volume; PTVim, internal mammary nodal planning target volume; NA, not available; LADCA, left anterior descending coronary artery; PRV, planning organs at risk volume; Vx, the relative volume irradiated to a minimum dose x Gy; Dmean, mean dose; Dmax, maximal dose
  2. ‡Comparison of the optimal plus acceptable rates between first and final submission
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us